BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Taxonera C, Rodríguez C, Bertoletti F, Menchén L, Arribas J, Sierra M, Arias L, Martínez-montiel P, Juan A, Iglesias E, Algaba A, Manceñido N, Rivero M, Barreiro-de Acosta M, López-serrano P, Argüelles-arias F, Gutierrez A, Busquets D, Gisbert JP, Olivares D, Calvo M, Alba C. Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis: . Inflammatory Bowel Diseases 2017;23:1394-402. [DOI: 10.1097/mib.0000000000001144] [Cited by in Crossref: 44] [Cited by in F6Publishing: 14] [Article Influence: 8.8] [Reference Citation Analysis]
Number Citing Articles
1 Olaiya B, Renelus BD, Filon M, Saha S. Trends in Morbidity and Mortality Following Colectomy Among Patients with Ulcerative Colitis in the Biologic Era (2002-2013): A Study Using the National Inpatient Sample. Dig Dis Sci 2021;66:2032-41. [PMID: 32676826 DOI: 10.1007/s10620-020-06474-1] [Reference Citation Analysis]
2 Pulusu SSR, Srinivasan A, Krishnaprasad K, Cheng D, Begun J, Keung C, Van Langenberg D, Thin L, Mogilevski T, De Cruz P, Radford-Smith G, Flanagan E, Bell S, Kashkooli S, Sparrow M, Ghaly S, Bampton P, Sawyer E, Connor S, Rizvi QUA, Andrews JM, Mahy G, Chivers P, Travis S, Lawrance IC. Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford. World J Gastroenterol 2020; 26(30): 4428-4441 [PMID: 32874055 DOI: 10.3748/wjg.v26.i30.4428] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
3 Chiba M, Tsuji T, Nakane K, Tsuda S, Ishii H, Ohno H, Obara Y, Komatsu M, Tozawa H. High Remission Rate with Infliximab and Plant-Based Diet as First-Line (IPF) Therapy for Severe Ulcerative Colitis: Single-Group Trial. Perm J 2020;24:1-10. [PMID: 33482946 DOI: 10.7812/TPP/19.166] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Li R, Huang X, Yang L, Liang X, Huang W, Lai KP, Zhou L. Integrated Analysis Reveals the Targets and Mechanisms in Immunosuppressive Effect of Mesalazine on Ulcerative Colitis. Front Nutr 2022;9:867692. [DOI: 10.3389/fnut.2022.867692] [Reference Citation Analysis]
5 Limdi JK. Golimumab for ulcerative colitis: adding perspective to the pursuit. Frontline Gastroenterol. 2018;9:232-233. [PMID: 30047548 DOI: 10.1136/flgastro-2017-100929] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
6 Guberna L, Nyssen OP, Chaparro M, Gisbert JP. Frequency and Effectiveness of Empirical Anti-TNF Dose Intensification in Inflammatory Bowel Disease: Systematic Review with Meta-Analysis. J Clin Med 2021;10:2132. [PMID: 34069295 DOI: 10.3390/jcm10102132] [Reference Citation Analysis]
7 Liefferinckx C, Cremer A, Franchimont D. Switching biologics used in inflammatory bowel diseases: how to deal with in practice? Curr Opin Pharmacol 2020;55:82-9. [PMID: 33166871 DOI: 10.1016/j.coph.2020.10.003] [Reference Citation Analysis]
8 Hoque S, Puenpatom A, Boccaletti S, Green C, Black CM, Roberts J, Rajkovic I, Milligan G. Treatment persistence and colectomy-free outcomes in patients with ulcerative colitis receiving golimumab or adalimumab: a UK experience. BMJ Open Gastroenterol 2020;7:e000476. [PMID: 33199269 DOI: 10.1136/bmjgast-2020-000476] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Attauabi M, Madsen GR, Bendtsen F, Seidelin JB, Burisch J. Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease - a systematic review with meta-analysis. Dig Liver Dis 2021:S1590-8658(21)00856-2. [PMID: 34903497 DOI: 10.1016/j.dld.2021.11.014] [Reference Citation Analysis]
10 Atreya R, Neurath MF, Siegmund B. Personalizing Treatment in IBD: Hype or Reality in 2020? Can We Predict Response to Anti-TNF? Front Med (Lausanne) 2020;7:517. [PMID: 32984386 DOI: 10.3389/fmed.2020.00517] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
11 Eriksson C, Visuri I, Vigren L, Nilsson L, Kärnell A, Hjortswang H, Bergemalm D, Almer S, Hertervig E, Karlén P, Strid H, Halfvarson J; GO SWIBREG study group. Clinical effectiveness of golimumab in ulcerative colitis: a prospective multicentre study based on the Swedish IBD Quality Register, SWIBREG. Scand J Gastroenterol 2021;56:1304-11. [PMID: 34415803 DOI: 10.1080/00365521.2021.1963466] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Probert CS, Sebastian S, Gaya DR, Hamlin PJ, Gillespie G, Rose A, Tate H, Wheeler C, Irving PM. Golimumab induction and maintenance for moderate to severe ulcerative colitis: results from GO-COLITIS (Golimumab: a Phase 4, UK, open label, single arm study on its utilization and impact in ulcerative Colitis). BMJ Open Gastroenterol 2018;5:e000212. [PMID: 30002864 DOI: 10.1136/bmjgast-2018-000212] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
13 Macaluso FS, Orlando A, Papi C, Festa S, Pugliese D, Bonovas S, Pansieri C, Piovani D, Fiorino G, Fantini MC, Caprioli F, Daperno M, Armuzzi A; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)., Working panel., Review panel. Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology. Dig Liver Dis 2022:S1590-8658(22)00137-2. [PMID: 35184989 DOI: 10.1016/j.dld.2022.01.127] [Reference Citation Analysis]
14 Albshesh A, Taylor J, Savarino EV, Truyens M, Armuzzi A, Ribaldone DG, Shitrit AB, Fibelman M, Molander P, Liefferinckx C, Nancey S, Korani M, Rutka M, Barreiro-de Acosta M, Domislovic V, Suris G, Eriksson C, Alves C, Mpitouli A, di Jiang C, Tepeš K, Coletta M, Foteinogiannopoulou K, Gisbert JP, Amir-Barak H, Attauabi M, Seidelin J, Afif W, Marinelli C, Lobaton T, Pugliese D, Maharshak N, Cremer A, Limdi JK, Molnár T, Otero-Alvarin B, Krznaric Z, Magro F, Karmiris K, Raine T, Drobne D, Koutroubakis I, Chaparro M, Yanai H, Burisch J, Kopylov U. Effectiveness of Third-Class Biologic Treatment in Crohn's Disease: A Multi-Center Retrospective Cohort Study. J Clin Med 2021;10:2914. [PMID: 34209880 DOI: 10.3390/jcm10132914] [Reference Citation Analysis]
15 Stefanovic S, Detrez I, Compernolle G, Brouwers E, Sever N, Stabuc B, Smrekar N, Kurent T, Novak G, Kozelj M, Ferrante M, Gils A, Drobne D. Endoscopic remission can be predicted by golimumab concentrations in patients with ulcerative colitis treated with the changed label. Eur J Gastroenterol Hepatol 2021;33:54-61. [PMID: 32804854 DOI: 10.1097/MEG.0000000000001843] [Reference Citation Analysis]
16 Viazis N, Pontas C, Manolakis A, Karampekos G, Tsoukali E, Galanopoulos M, Koustenis K, Archavlis E, Christidou A, Gazouli M, Mantzaris GJ. Efficacy of switching from infliximab to golimumab in patients with ulcerative colitis in deep remission. Acta Gastroenterol Belg 2021;84:423-8. [PMID: 34599566 DOI: 10.51821/84.3.007] [Reference Citation Analysis]
17 Pugliese D, Privitera G, Rogai F, Variola A, Viola A, Laterza L, Privitera AC, Allocca M, Bossa F, Cappello M, Daperno M, Lorenzon G, Mazzuoli S, Principi M, Sablich R, Moser L, Ferronato A, Traini S, Tapete G, Bodini G, Di Girolamo M, Grossi L, Mocci G, Ricci C, Saibeni S, Festa S, Spagnuolo R, Cortelezzi CC, Mocciaro F, Rizzello F, Armuzzi A; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study. United European Gastroenterol J 2021;9:102-9. [PMID: 33203342 DOI: 10.1177/2050640620974308] [Reference Citation Analysis]
18 Detrez I, Schops G, Lefrère J, Tops S, Van Assche G, Vermeire S, Van Moerkercke W, Ferrante M, Gils A. Golimumab Dried Blood Spot Analysis (GOUDA): a Prospective Trial Showing Excellent Correlation with Venepuncture Samples and More Detailed Pharmacokinetic Information. AAPS J 2018;21:10. [PMID: 30564993 DOI: 10.1208/s12248-018-0282-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
19 Melo AT, Campanilho-Marques R, Fonseca JE. Golimumab (anti-TNF monoclonal antibody): where we stand today. Hum Vaccin Immunother 2021;17:1586-98. [PMID: 33369527 DOI: 10.1080/21645515.2020.1836919] [Reference Citation Analysis]
20 Cunningham G, Samaan MA, Irving PM. Golimumab in the treatment of ulcerative colitis. Therap Adv Gastroenterol 2019;12:1756284818821266. [PMID: 30728858 DOI: 10.1177/1756284818821266] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Perrig K, Krupka N, Jordi SBU, Rossel J, Biedermann L, Greuter T, Schreiner P, Vavricka SR, Juillerat P, Burri E, Zimmermann D, Maillard MH, Sulz MC, Brand S, Rogler G, Misselwitz B. Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland. Therap Adv Gastroenterol 2022;15:175628482210741. [DOI: 10.1177/17562848221074188] [Reference Citation Analysis]
22 Tursi A. Performances of anti-TNFα antibodies as long-term maintenance therapy for ulcerative colitis. Eur J Gastroenterol Hepatol 2021;33:e1107-8. [PMID: 35048684 DOI: 10.1097/MEG.0000000000002220] [Reference Citation Analysis]
23 Reinglas J, Gonczi L, Kurt Z, Bessissow T, Lakatos PL. Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases. World J Gastroenterol 2018; 24(32): 3567-3582 [PMID: 30166855 DOI: 10.3748/wjg.v24.i32.3567] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]